Evidence map›Paper›PMID 41458923›Full record

ArticleNeuro-oncology practice2025

Dabrafenib in pediatric patients with

Birgit Geoerger, Lucas Moreno, Eric Bouffet, Santhosh A Upadhyaya, Nicolas André, Isabelle Aerts, Ashley S Plant-Fox, Michael Roughton, Mark Russo, Darren Hargrave

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Birgit GeoergerGustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, INSERM U1015, Université Paris-Saclay, Villejuif, France.
Lucas MorenoDepartment of Pediatric Oncology & Hematology, Vall d'Hebron Hospital, Barcelona, Spain.
Eric BouffetDepartment of Hematology & Oncology, The Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6832-6539
Santhosh A UpadhyayaAuthor's current affiliation: Department of Pediatrics, C.S. Mott Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Nicolas AndréDepartment of Hematology & Pediatric Oncology, Assistance Publique Hôpitaux de Marseille (AP-HM), CRCM, Aix Marseille University, Marseille, France.
Isabelle AertsInstitut Curie, PSL Research University, Oncology Center SIREDO, Paris, France.ORCID https://orcid.org/0000-0002-5213-3353
Ashley S Plant-FoxDepartment of Pediatric Hematology, Oncology, Stem Cell Transplantation, and Neuro-Oncology, Ann and Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Michael RoughtonNovartis Pharma AG, Basel, Switzerland.
Mark RussoNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Darren HargraveUCL Great Ormond Street Institute for Child Health, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Patients aged 1 to < 18 years with Results: Overall, 35 pediatric patients with HGG were treated. Histologic diagnosis included pleomorphic xanthoastrocytoma ( Conclusions: In pediatric patients with relapsed orrefractory

Indexed as

BRAF inhibitorsBRAF V600EDabrafenibpediatric gliomasrecurrent/refractory HGG

Identifiers

PMID41458923
PMCPMC12741824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.